| Quarterly Financials | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 13 | 30 | 22 | 15 | 23 | 22 | 19 | 29 | 17 | 19 | 16 | 13 | 16 | 24 | 22 | 18 | 18 | 21 | 21 | 24 |
| Expenses | 13 | 24 | 22 | 19 | 22 | 26 | 25 | 32 | 26 | 27 | 24 | 16 | 20 | 25 | 25 | 27 | 20 | 24 | 22 | 25 |
| EBITDA | -0 | 6 | -0 | -4 | 1 | -4 | -6 | -4 | -9 | -9 | -8 | -4 | -4 | -1 | -3 | -9 | -2 | -3 | -2 | -1 |
| Operating Profit % | -2 % | 18 % | -3 % | -31 % | -2 % | -20 % | -34 % | -14 % | -50 % | -51 % | -56 % | -29 % | -25 % | -5 % | -15 % | -54 % | -11 % | -16 % | -7 % | -5 % |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -3 | 3 | -3 | -7 | -2 | -7 | -9 | -7 | -11 | -12 | -11 | -4 | -5 | -2 | -4 | -10 | -2 | -4 | -2 | -1 |
| Tax | 0 | 0 | 0 | 10 | -1 | -2 | -1 | -1 | -2 | -4 | -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -3 | 3 | -3 | -17 | -1 | -5 | -7 | -6 | -9 | -8 | -10 | -4 | -5 | -2 | -4 | -10 | -2 | -4 | -2 | -2 |
| EPS in ₹ | 0.00 | 1.35 | -1.03 | -6.93 | -0.47 | -1.97 | -3.14 | -1.46 | -3.80 | -3.19 | -2.03 | -1.75 | -1.81 | -0.60 | -1.51 | -3.77 | -0.94 | -1.51 | -1.75 | -0.54 |
Brooks Laboratories
132.91
-5.61
(-4.05%)
Market Cap
391.52 Cr
EPS
-7.65
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
198.86
52 Week Low
74.00
PB Ratio
4.20
Debt to Equity
0.09
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.20 | #1 4,02,896.33 | 35.21 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 43.89 | |
6,544.50 | 1,73,735.91 | 80.34 | 8,184.00 | 0.89 | 1,600 | 23.05 | 57.72 | |
1,504.20 | 1,21,481.44 | 22.82 | 26,520.70 | 14.17 | 4,155 | 30.28 | 55.17 | |
1,320.90 | 1,10,223.21 | #1 19.03 | 28,905.40 | 12.36 | 5,578 | 21.14 | 80.62 | |
3,154.30 | 1,06,755.85 | 55.19 | 10,785.70 | 11.59 | 1,656 | 10.91 | 44.00 | |
2,352.40 | 97,054.97 | 49.05 | 10,615.60 | 19.57 | 1,942 | -10.91 | 37.92 | |
960.15 | 96,613.56 | 20.59 | 19,831.50 | 13.82 | 3,831 | -0.19 | 71.38 | |
1,999.60 | 91,289.93 | 27.77 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 50.41 | |
1,161.10 | 67,436.88 | 19.49 | 29,559.20 | 17.55 | 3,169 | -0.50 | 47.11 | |
31,630.00 | 67,211.54 | 47.62 | 6,097.20 | 10.80 | 1,201 | 27.83 | 63.13 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
26.81 %
Net Income Growth
-36.77 %
Cash Flow Change
33.20 %
ROE
-28.85 %
ROCE
-41.22 %
EBITDA Margin (Avg.)
-112.56 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 162 | 196 | 110 | 90 |
| Fixed Assets | 108 | 110 | 15 | 14 |
| Current Assets | 47 | 61 | 28 | 31 |
| Capital Work in Progress | 1 | 15 | 0 | 0 |
| Investments | 0 | 0 | 64 | 43 |
| Other Assets | 54 | 71 | 31 | 34 |
| Total Liabilities | 162 | 196 | 110 | 90 |
| Current Liabilities | 64 | 49 | 33 | 23 |
| Non Current Liabilities | 19 | 13 | 3 | 2 |
| Total Equity | 79 | 134 | 74 | 66 |
| Reserve & Surplus | 54 | 63 | 49 | 39 |
| Share Capital | 25 | 25 | 25 | 26 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 1 | 2 | -3 | 0 |
| Investing Activities | -5 | -25 | 1 | 0 |
| Operating Activities | 5 | -37 | -15 | -10 |
| Financing Activities | 1 | 64 | 11 | 10 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Jan 2025 | Mar 2025 |
| Promoter | 66.41 % | 66.41 % | 66.41 % | 66.41 % | 66.41 % | 66.41 % | 66.41 % | 66.41 % | 66.41 % | 66.41 % | 63.59 % | 63.59 % | 63.59 % | 63.59 % | 63.59 % | 63.59 % | 59.06 % | 52.62 % | 52.62 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.02 % | 0.01 % | 0.00 % | 0.05 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.06 % | 0.06 % | 0.00 % | 1.25 % | 2.46 % | 3.86 % | 3.86 % | 3.86 % | 3.86 % | 3.86 % | 9.90 % | 10.38 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 28.74 % | 28.92 % | 28.73 % | 28.84 % | 28.79 % | 28.75 % | 28.20 % | 27.80 % | 27.72 % | 27.84 % | 27.80 % | 26.89 % | 25.21 % | 25.55 % | 25.57 % | 28.55 % | 32.34 % | 32.13 % | 31.86 % |
| Others | 4.84 % | 4.67 % | 4.85 % | 4.74 % | 4.80 % | 4.83 % | 5.39 % | 5.73 % | 5.81 % | 5.74 % | 7.36 % | 7.06 % | 7.34 % | 7.00 % | 6.98 % | 3.99 % | 4.74 % | 5.35 % | 5.08 % |
| No of Share Holders | 10,702 | 10,429 | 10,379 | 10,916 | 11,145 | 11,104 | 10,524 | 10,410 | 10,709 | 11,216 | 11,141 | 10,686 | 10,028 | 11,432 | 11,543 | 11,282 | 10,521 | 10,374 | 10,537 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
No dividends have been distributed by the company in the past 10 years
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 May 2025 |  Quarterly Result Announcement | NA | 28 May 2025 | 136.25 | 132.16 |
| 13 Feb 2025 | Quarterly Result Announcement | NA | 13 Feb 2025 | 155.85 | 136.15 |
| 11 Jan 2025 |  Extraordinary General Meeting | NA | 11 Jan 2025 | 159.15 | 184.60 |
| 09 Nov 2024 | Quarterly Result Announcement | NA | 09 Nov 2024 | 149.26 | 143.10 |
| 19 Sept 2024 |  Annual General Meeting | NA | 19 Sept 2024 | 122.71 | 153.65 |
| 21 Sept 2023 | Annual General Meeting | NA | 21 Sept 2023 | 94.00 | 99.89 |
| 28 Jul 2023 |  Rights | 1:16 | 28 Jul 2023 | 78.74 | 88.60 |
| Rights | 9:20 | 11 Feb 2020 | 35.14 | 0.00 |
Announcements
Compliances-Reg.24(A)-Annual Secretarial Compliance
8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication8 days ago
8 days agoAnnouncement Under Regulation 30 - Appointment Of Secretarial Auditor.9 days ago
9 days agoBoard Meeting Outcome for Outcome Of Board Meeting Held On Wednesday 28Th May 20259 days ago
9 days agoOutcome Of Board Meeting Held On Wednesday 28Th May 20259 days ago
9 days agoBoard Meeting Intimation for Intimation Under Regulation 29 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.May 23, 2025
May 23, 2025Intimation Of Legal Proceedings Initiated Under IBC 2016 By KNAV Corporate Finance.May 16, 2025
May 16, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Apr 29, 2025Intimation Of Update In Registrar And Transfer Agent (RTA) Contact DetailsApr 19, 2025
Apr 19, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December 2024 (Revised).Feb 28, 2025
Feb 28, 2025Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December 2024 (Revised).Feb 28, 2025
Feb 28, 2025Outcome Of Board Meeting (Revised).Feb 25, 2025
Feb 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Feb 14, 2025Integrated Filing (Financial)Feb 13, 2025
Feb 13, 2025Unaudited Financial Results Both Standalone And Consolidated For The Quarter And Nine Months Ended 31St December 2024Feb 13, 2025
Feb 13, 2025Board Meeting Outcome for Board Meeting Outcome Under Regulation 30 & Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 13, 2025
Feb 13, 2025Board Meeting Intimation for Intimation Under Regulation 29 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Feb 10, 2025
Feb 10, 2025Board Meeting Outcome for Allotment Of 3210510 Equity Shares On Preferential Basis.Jan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-AllotmentJan 29, 2025
Jan 29, 2025Announcement Under Regulation 30 (LODR) - General Updates On Preferential IssueJan 24, 2025
Jan 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 21, 2025
Jan 21, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 13, 2025
Jan 13, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMJan 11, 2025
Jan 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 09, 2025
Jan 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 08, 2025
Jan 08, 2025Corrigendum To The EOGM Notice Dated 17Th
December 2024.Jan 07, 2025
Jan 07, 2025Intimation Regarding The Change Of Name Of Registrar And Share Transfer Agent (RTA)Jan 03, 2025
Jan 03, 2025Closure of Trading WindowDec 31, 2024
Dec 31, 2024Board Meeting Outcome for Outcome Of Fund Raising Committee For Approval Of Equity Share Through Preferential IssueDec 17, 2024
Dec 17, 2024Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, December 11, 2024Dec 11, 2024
Dec 11, 2024Board Meeting Intimation for Fund RaisingDec 07, 2024
Dec 07, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Nov 18, 2024
Nov 18, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Nov 18, 2024
Nov 18, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Nov 18, 2024
Nov 18, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Nov 18, 2024
Nov 18, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Nov 18, 2024
Nov 18, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2024
Nov 11, 2024Unaudited Financial Results, Both Standalone And Consolidated, For The Quarter And Half Year Ended 30Th September, 2024Nov 09, 2024
Nov 09, 2024Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 & Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015Nov 09, 2024
Nov 09, 2024Board Meeting Intimation for Approval Of The Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024.Nov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Credit RatingNov 05, 2024
Nov 05, 2024Announcement under Regulation 30 (LODR)-CessationOct 19, 2024
Oct 19, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 19, 2024
Oct 19, 2024Announcement under Regulation 30 (LODR)-CessationOct 04, 2024
Oct 04, 2024Closure of Trading WindowSep 30, 2024
Sep 30, 2024Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerSep 21, 2024
Sep 21, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateSep 19, 2024
Sep 19, 2024Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sSep 19, 2024
Sep 19, 2024Technical Indicators
RSI(14)
Neutral 46.29
ATR(14)
Less Volatile 7.13
STOCH(9,6)
Neutral 62.28
STOCH RSI(14)
Neutral 33.34
MACD(12,26)
Bearish -0.14
ADX(14)
Weak Trend 15.95
UO(9)
Bearish 42.44
ROC(12)
Downtrend And Accelerating -2.59
WillR(14)
Oversold -82.43
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 Quant Business Cycle Fund Direct-Growth | 0 | 0.00% | -3.02% | -2.51% | May 2025 | |
| Quant Healthcare Fund Direct - Growth | 0 | 0.00% | 0.00% | 0.00% | May 2025 |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
